Exagen Inc. (XGN)

NASDAQ: XGN · IEX Real-Time Price · USD
8.12 -0.27 (-3.22%)
Jan 21, 2022 4:00 PM EST - Market closed

Company Description

Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States.

It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS.

In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d.

Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers.

The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Inc.
Exagen Logo
CountryUnited States
IPO DateSep 19, 2019
IndustryHealth Care Providers & Services
SectorHealth Care
CEOFortunato Rocca

Contact Details

1261 Liberty Way Ste C
Vista, California 92081-8356
United States
Phone760 560 1501

Stock Details

Ticker SymbolXGN
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$14.00
CIK Code1274737

Key Executives

Fortunato RoccaChief Executive Officer, President and Director
Kamal Adawi M.S., MBAChief Financial Officer and Corporate Secretary
Dr. Debra Jeske ZackChief Medical Officer
Mark HazeltineChief Operating Officer
Dr. Ming-Chou Lee Ph.D.Chief Technology Officer
Dr. Anja Kammesheidt Ph.D.Chief Scientific Officer
John WegenerSenior Vice President of Sales and Marketing

Latest SEC Filings

Jan 10, 20228-KCurrent report
Dec 23, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Dec 17, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 10, 20218-KCurrent report
Oct 25, 20218-KCurrent report
Oct 19, 20218-KCurrent report
Sep 7, 20214Statement of changes in beneficial ownership of securities
Aug 27, 20218-KCurrent report
Aug 9, 202110-QQuarterly report [Sections 13 or 15(d)]
View All SEC Filings